Showing that his loyalty to his own anti-vax mentality is greater than his loyalty to President Donald Trump, Robert F. Kennedy Jr., the dangerous quack atop the Department of Health and Human ...

Parents won't be able to vaccinate healthy children 6 months to 5 years old if the FDA pulls Pfizer's COVID-19 vaccine authorization.

The update on this clinical study could influence BioNTech’s stock performance by potentially boosting investor confidence if the results are favorable. The involvement of collaborators like ...

The Food and Drug Administration could pull Pfizer's coronavirus vaccine emergency authorization for children under age 5.

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

Shortly after that, the CDC overhauled its vaccine recommendations in COVID, nixing its endorsement of the shots for pregnant women and healthy children. At the time, RFK Jr. said he “couldn’t be more ...

Pfizer (PFE) stock and BioNTech (BNTX) stock in focus as FDA may not renew the authorization for their pediatric COVID shot. Read more here.

After BioNTech’s acquisition of CureVac closes, BioNTech will pay GSK another $130 million and a 1% royalty on rest-of-world ...

“Stratus,” originally known as Variant XFG, is the second most prominent strain of COVID in the United States. According to ...

The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition ...

Stocks in the health-care industry rose as markets grew more confident that U.S. borrowing costs will fall, while companies in the sector pleased investors in their quarterly reports. Gilead Sciences ...

26 April 2024 New claim from GlaxoSmithKline is latest in litany of lawsuits against rivals | US lawsuit, potentially worth ...